Despite a growing sentiment favoring industrial and dividend stocks in 2026, three high-risk stocks that surged over 100% in 2025 continue to show upside potential. FTAI Aviation benefits from GE Aerospace and Palantir partnerships, Kratos Defense gains from defense sector positioning, and Monte Rosa Therapeutics shows promise from positive clinical trial data. All three trade near or below analyst price targets with further upside expected.

Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company developing molecular glue degrader medicines, announced pricing of an underwritten public offering of 11.125 million shares at $24.00 per share and 1.375 million pre-funded warrants, expected to raise approximately $300 million gross proceeds. The offering is expected to close on January 12, 2026.

Monte Rosa Therapeutics presented preclinical data on MRT-8102, a molecular glue degrader targeting NEK7, which shows potential in treating cardiovascular and cardiometabolic diseases by modulating the NLRP3 inflammasome pathway.

Monte Rosa Therapeutics announced CEO Markus Warmuth will participate in multiple healthcare investor conferences in November and December 2025, presenting the company's molecular glue degrader (MGD) research and developments.

Monte Rosa Therapeutics presented preclinical data on MRT-6160, a molecular glue degrader targeting VAV1, showing potential to treat multiple autoimmune and inflammatory diseases like systemic lupus erythematosus and rheumatoid arthritis in mouse models.

Monte Rosa Therapeutics announced a collaboration with Novartis to develop novel AI-powered degraders for immune-mediated diseases, receiving $120 million upfront and potential milestone payments up to $5.7 billion.

Monte Rosa Therapeutics signed a collaboration agreement with Novartis to develop novel molecular glue degraders for immune-mediated diseases, receiving a $120 million upfront payment and potential milestone payments up to $5.7 billion.

Monte Rosa Therapeutics initiated a Phase 1 clinical study for MRT-8102, a molecular glue degrader targeting NEK7 for treating inflammatory diseases. The study includes single and multiple ascending dose cohorts in healthy volunteers, with initial results expected in H1 2026.

Monte Rosa Therapeutics published groundbreaking research in Science, using AI and machine learning to expand the potential target space for molecular glue degrader medicines, identifying over 100 protein target classes previously considered undruggable.

Monte Rosa Therapeutics announced FDA clearance of an IND application for MRT-8102, a NEK7-directed molecular glue degrader being developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation. The company plans to initiate a Phase 1 study of MRT-8102 in the coming weeks and expects to share initial results in H1 2026.

Monte Rosa Therapeutics presented preclinical data on its CDK2-directed molecular glue degrader, MRT-51443, which showed potential to treat HR-positive/HER2-negative breast cancer when combined with CDK4/6 inhibition and anti-estrogen therapy.

Monte Rosa Therapeutics, a clinical-stage biotechnology company, announced that its CEO will present at the upcoming J.P. Morgan Healthcare Conference. The company is developing molecular glue degrader-based medicines for various diseases.